d. The Respondent increased patients’ opioid doses based on subjective
complaints of pain but failed to document objective findings to carefully
justify increasing opioid doses significantly above the CDC Guideline
(Patients 1-10);

e. The Respondent failed to consider or refer patients for alternative
treatments such as physical or chiropractic therapy, and/or interventional
injection treatments (Patients 1, 4, 5, 6, 7, and 10);

f. The Respondent failed to require that patients obtain EKG studies to
assess any cardiac changes from certain opioids (Patients 5 and 8); and

g. The Respondent prescribed benzodiazepines to patients who were also
prescribed high-dose opiates without verifying anxiety diagnoses with a
mental health provider, and without providing appropriate or accurate
counseling on how to avoid dangerous or fatal interactions between the
drugs (Patients 2, 4, 6, and 8).

D. The Respondent’s Response to Peer Review Reports

19. Onor about May 14, 2020, the Respondent submitted a response to the Board
after being provided copies of the peer reviewers’ reports. The Respondent stated that,
among other things, he is “aware of the current standard of less than 90 MME/day of oral
morphine,” but that “the CDC also indicated that this is just a guideline and mostly applies
to primary care providers.” The Respondent also stated that he treats patients “holistically”
and must “thread the needle” to make sure remedial actions such as discharging patients
with aberrant behavior “were not taken at the wrong time during their treatment[.]”

E. The Respondent’s Dispensing Practices

20. On or about December 7, 2018, OCSA inspected the Respondent’s office.
The inspectors noted in their inspection report that the Respondent stocked and dispensed
phentermine (a Schedule IV CDS), among other weight-loss medications and antibiotics.

The inspectors found multiple violations, including:
